124341-37-3

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 3-(methylamino)-2-nitro(9CI) is used as an intermediate in the synthesis of Endophenazine B (E555485), a novel phenazine antibiotic. This antibiotic demonstrates potent antimicrobial activities against Gram-positive bacteria and some filamentous fungi, making it a valuable compound in the development of new antibiotics to combat drug-resistant infections.
Additionally, Benzoic acid, 3-(methylamino)-2-nitro(9CI) exhibits herbicidal activity against Lemna minor (duckweed), a problematic aquatic weed that can cause significant ecological and agricultural issues. Its use in the development of herbicides can help control the growth of such invasive species, thereby contributing to more sustainable agricultural practices and environmental management.

Upstream product

• 4771-47-5 3-chloro-2-nitro-benzoic acid 
• 74-89-5 methylamine 
• 42087-81-0 3-chloro-2-nitro-benzoic acid methyl ester 
• 208772-18-3 methyl 3-(N-Methylacetamido)-2-nitrobenzoate 
• 208772-05-8 3-(N-acetyl-N-methylamino)-2-nitrobenzoic acid 

Downstream Products

• 1258070-61-9 methyl 2-amino-3-(methylamino)benzoate 
• 124340-49-4 1-Methyl-2-phenyl-1H-benzoimidazole-4-carboxylic acid (2-dimethylamino-ethyl)-amide 
• 124340-80-3 1-methyl-2-phenyl-1H-benzimidazole-4-carboxylic acid 

Relevant academic research and scientific papers

Cyclosporin derivatives

The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases,

Triptycene-based, carboxylate-bridged biomimetic diiron(II) complexes

A triptycene-based bis(benzimidazole) ester ligand, L3, was designed to enhance the electron-donating ability of the heterocyclic nitrogen atoms relative to those of the first-generation bis(benzoxazole) analogs, L1 and L2. A convergent synthesis of L3 was designed and executed. Three-component titration experiments using UV/Vis spectroscopy revealed that the desired diiron(II) complex could be obtained with a 1:2:1 ratio of L3/Fe(OTf)2(MeCN) 2/external carboxylate reactants. X-ray crystallographic studies of two diiron complexes derived in this manner from L3 revealed their formulas to be [Fe2L3(μ-OH)(μ-O2CR)(OTf)2], where R = 2,6-bis(p-tolyl)phenyl (7) or triphenylmethyl (8). The structures are similar to that of a diiron complex derived from L1, [Fe2L1(μ-OH)(μ- O2CArTol)(OTf)2] (9), a notable difference being that, in 7 and 8, the geometry at iron more closely resembles square-pyramidal than trigonal-bipyramidal. Moessbauer spectroscopic analyses of 7 and 8 indicate the presence of high-spin diiron(II) cores. These results demonstrate the importance of substituting benzimidazole for benzoxazole for assembling biomimetic diiron complexes with syn disposition of two N-donor ligands, as found in O2-activating carboxylate-bridged diiron centers in biological systems. Copyright

Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of "Minimal" DNA-Intercalating Agents Which May Not Act via Topoisomerase II

A series of substituted 2-phenylbenzimidazole-4-carboxamides has been synthesized and evaluated for in vitro and in vivo antitumor activity.These compounds represent the logical conclusion to our search for "minimal" DNA-intercalating agents with the lowest possible DNA-binding constants.Such "2-1" tricyclic chromophores, of lower aromaticity than the structurally similar 2-phenylquinolines, have the lowest DNA binding affinity yet seen in the broad series of tricyclic carboxamide intercalating agents.Despite very low in vitro cytotoxicities, several of the compoundshad moderate levels of in vivo antileukemic effects.However, the most interesting aspect of their biological activity was the lack of cross-resistance shown to an amsacrine-resistant P388 cell line, suggesting that these compounds may not express their cytotoxicity via interaction with topoisomerase II.